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Faecal biomarkers in type 1 
diabetes with and without diabetic 
nephropathy
Signe Abitz Winther1,2,11, Miia Maininki Mannerla3,4,5,11, Marie Frimodt‑Møller1, 
Frederik Persson1, Tine Willum Hansen1, Markku Lehto3,4,5, Sohvi Hörkkö6,7, Michael Blaut8, 
Carol Forsblom3,4,5, Per‑Henrik Groop3,4,5,9 & Peter Rossing 1,10*
Gastrointestinal dysbiosis is common among persons with type 1 diabetes (T1D), but its potential 
impact on diabetic nephropathy (DN) remains obscure. We examined whether faecal biomarkers, 
previously associated with low‑grade gastrointestinal inflammation, differ between healthy controls 
and T1D subjects with and without DN. Faecal samples were analyzed for levels of calprotectin, 
intestinal alkaline phosphatase (IAP), short‑chain fatty acids (SCFA) and immunoglobulins in subjects 
with T1D (n = 159) and healthy controls (NDC; n = 50). The subjects with T1D were stratified based 
on albuminuria: normoalbuminuria (< 30 mg/g; n = 49), microalbuminuria (30–299 mg/g; n = 50) and 
macroalbuminuria (≥ 300 mg/g; n = 60). aecal calprotectin, IAP and immunoglobulin levels did not 
differ between the T1D albuminuria groups. However, when subjects were stratified based on faecal 
calprotectin cut‑off level (50 µg/g), macroalbuminuric T1D subjects exceeded the threshold more 
frequently than NDC (p = 0.02). Concentrations of faecal propionate and butyrate were lower in 
T1D subjects compared with NDC (p = 0.04 and p = 0.03, respectively). Among T1D subjects, levels 
of branched SCFA (BCFA) correlated positively with current albuminuria level (isobutyrate, p = 0.03; 
isovalerate, p = 0.005). In our study cohort, fatty acid metabolism seemed to be altered among T1D 
subjects and those with albuminuria compared to NDC. This may reflect gastrointestinal imbalances 
associated with T1D and renal complications.
The human gut microbiota is shaped throughout life by genetic and environmental  factors1. Gut bacteria metabo-
lize dietary nutrients, harvest energy from the diet, and produce essential vitamins for the need of the host. 
The human gut environment contributes to important functions of the immune system, and even a short-term 
use of antibiotics may change the balance between beneficial and pathogenic  bacteria2, 3. Over the past decade, 
alterations in gut microbiota composition, known as gut dysbiosis, have been linked to a wide range of diseases 
such as inflammatory bowel disease (IBD), cancer, atherosclerosis, diabetes, obesity, liver diseases, psychological 
disorders, infections, and autoimmune  diseases4–6.
IBD and celiac disease are multifactorial autoimmune diseases affecting the small intestine and colon. Subjects 
with such chronic gastrointestinal conditions are susceptible to extra-intestinal tissue damage associated with 
other vital internal organs such as liver, pancreas, lungs, and  kidneys7. Subjects with IBD, celiac disease and type 
1 diabetes (T1D) share many genetic and phenotypic  features8. In T1D, the incidence and severity of gastroin-
testinal symptoms seem to correlate with the progression of diabetic complications, e.g.  neuropathy9. However, 
due to the lack of systematic screenings, the prevalence of gastrointestinal disorders and their potential impact 
on the development of late diabetic complications remains obscure. We have recently shown that subjects with 
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T1D exhibit aberrant profiles of gut microbiota and plasma metabolites compared to healthy controls. Moreover, 
T1D subjects with different albuminuria levels show different gut microbiota and plasma metabolite  profiles10.
Based on this background, we analyzed a set of gastrointestinal  biomarkers10 previously associated with intes-
tinal inflammation (calprotectin), gut metabolite production (short-chain fatty acids), detoxification of bacterial 
endotoxins (intestinal alkaline phosphatase), and host defense (immunoglobulins) to investigate whether these 
faecal markers of gut metabolism are associated with albuminuria in a Danish cohort of adult T1D subjects with 
and without diabetic nephropathy.
Materials and methods
Study population. Between April 2016 and December 2017 subjects with T1D were recruited to participate 
in a cross-sectional study from the outpatient clinic at Steno Diabetes Center Copenhagen (SDCC) in Denmark. 
With the cohort, we aimed to perform a detailed phenotyping of T1D subjects with or without renal complica-
tions, including subjects of more than 18 years old and diagnosed with T1D according to the 2006 WHO cri-
teria. Based on the highest historical or the present level of albuminuria, subjects with T1D were stratified into 
subgroups of normoalbuminuria (< 30 mg/24-h or 30 mg/g creatinine), microalbuminuria (30–299 mg/24-h or 
mg/g creatinine) or macroalbuminuria (≥ 300 mg/24-h or 300 mg/g creatinine). The historical albuminuria was 
based on two out of three consecutive urine samples collected within 1 year. Subjects with normoalbuminuria 
did not have any history of micro- or macroalbuminuria prior to or at enrolment. In total, 161 subjects with 
T1D and 50 healthy non-diabetic controls (NDC) were included. One faecal sample was missing, and one sam-
ple did not have sufficient material for analyses leaving 159 T1D faecal samples for analyses. The control group 
was recruited via a newspaper advertisement distributed within the area of the Copenhagen region, Denmark. 
The exclusion criteria for all participants were: (1) non-diabetic kidney disease; (2) renal failure (eGFR < 15 ml/
min/1.73  m2), dialysis or kidney transplantation; (3) change in renin–angiotensin aldosterone system blocking 
treatment during the last month; (4) treatment with systemic antibiotics during the last two months; (5) treat-
ment with systemic immunosuppressive treatment. Subjects were matched for age and sex between groups.
Clinical and laboratory data. An enzyme immunoassay was used to measure the urinary albumin creati-
nine ratio (UACR) in three consecutive morning urine samples. The three urine samples were used to calculate 
the geometric mean of UACR for each subject, which is referred to as the current albuminuria level. High per-
formance liquid chromatography was used to measure  HbA1C. Plasma creatinine and cholesterol were measured 
by an enzymatic method (Vitros 5600, Ortho Clinical Diagnostics, USA) and eGFR was calculated using the 
chronic kidney disease-epidemiology collaboration (CKD-EPI)  equation11. High-sensitivity C-reactive protein 
(hsCRP) was measured by a latex-enhanced turbidimetric immunoassay method (Cobas 8000 modul c502, 
Roche Diagnostics, USA). Body weight (to nearest 0.5 kg) and height (to nearest 0.5 cm) of each subject were 
measured and used to calculate body mass index (body weight/height2 [kg/m2]). Twenty four-hour blood pres-
sure (24-h BP) was recorded by an oscillometric device using an appropriately sized cuff placed on the upper arm 
and programmed to measure blood pressure every 15 min between 7 am and 10 pm and every 30 min between 
10 pm and 7 am (Takeda, TM2430, Japan)12. Detailed medical history was obtained including current medica-
tion and history of diabetes complications, and the information was cross-referenced with electronic patient 
records. Retinopathy status was acquired from retinal images taken regularly (approximately every 1–2 years) 
at the outpatient clinic at SDCC. Retinopathy was graded as nil, presence of or historical non-proliferative or 
proliferative, based on the worst eye. Peripheral neuropathy status was defined according to the latest registered 
vibrations perception measured by biothesiometry. Neuropathy was defined as present, when the mean vibra-
tion perception of the left and the right foot was above the age, height and sex-adjusted  threshold13. Subjects 
completed a questionnaire on health and lifestyle, including information on smoking, alcohol consumption, 
physical activity, bowel movement and stool consistency according to the Bristol stool  scale14. Current smokers 
were defined as smoking one or more cigarettes/cigars/pipes per day.
Faecal sample collection. Subjects were instructed to collect a faecal sample at home no later than 2 weeks 
after the visit, following a standardized procedure including antiseptic handling, collection in sterile tubes and 
immediately freezing the sample in the subjects’ freezers at − 18 °C. No later than 72 h after delivery the frozen 
samples were transferred to the laboratory on dry ice and stored at − 80 °C until further analysis in Finland.
Faecal calprotectin. Faecal calprotectin concentrations were determined with the human calprotectin 
enzyme-linked immunosorbent (ELISA) assay according to manufacturer’s instructions (Bühlmann Labora-
tories, Switzerland). The assay relies on tetramethylbenzidine substrate and anti-calprotectin antibodies con-
jugated to horseradish peroxidase. Faecal samples, for which one measurement was missing for calprotectin 
(n = 208) (50–100 mg), were homogenized at + 4 °C and centrifuged at 2842g (5200 rpm) for 5 min. The faecal 
extractions were diluted 1:50 for the ELISA assay. Finally, the absorbances were read at 450 nm using Synergy 
H1 Microplate Reader (BioTek, Winooski, VT, USA). According to the manufacturer’s guidelines, the faecal 
calprotectin concentrations were categorized as “no inflammation” (< 50 μg/g), “moderate inflammation” (50–
200 μg/g), and “severe inflammation” (> 200 μg/g). This cut-off classification has been validated for monitoring 
and evaluating disease status of  IBD15.
Faecal short chain fatty acids. Faecal short chain fatty acids (SCFA) were measured with an HP 5890 
series gas chromatograph (Hewlett-Packard, Waldbronn, Germany) equipped with an HP-FFAP column and a 
flame ionization detector as described  earlier16. Briefly, 300 mg of fresh stool samples were diluted 1:5 in water 
and centrifuged 15000g for 5 min. A volume of 23.6 µl 12 mM isobutyric acid (as an internal standard), 280 µl 
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0.36 M  HClO4, and 270 µl 1 M NaOH were added to 50 µl of the supernatant. The mixture was lyophilized, and 
the residue was re-dissolved in a mixture of 400 µl acetone and 100 µl 5 M formic acid. After centrifugation 
(14,000g for 5 min), 1 µl of the supernatant was injected into the gas chromatograph. Authentic standards were 
used in all runs in order to determine levels of faecal C2, C3, C4, C5, iC4 and iC5. The ratios between SCFA 
(sum of C2, C3, C4 and C5 concentrations) and BCFA (sum of iC4 and iC5 concentrations) were calculated. 
Eighteen percent (37/209) of the study subjects could not provide a sufficient amount of faecal material for the 
SCFA analysis. Therefore, the final number of SCFA samples was 172.
Faecal intestinal alkaline phosphatase activity. Faecal intestinal alkaline phosphatase (IAP) activ-
ity was measured by an in-house colorimetric assay as described  earlier17. Briefly, faecal samples (50 mg) were 
homogenized in 500  μl extraction buffer (0.1  mM  ZnCl2, 1  mM  MgCl2, 10  mM Tris–HCl pH 8.0) contain-
ing sodium calcium edetate (EDTA)-free protease inhibitor cocktail (1:50) (Roche Diagnostics, Germany), and 
0.1 mm glass beads (Precellys, Bergin Technologies, Montigny, France). After homogenization, samples were 
centrifuged at 11,150g (13,000 rpm) for 10 min at + 4 °C. Supernatants were subjected to determinations of fae-
cal IAP activity and total protein concentrations. IAP assay standards were prepared using serial dilutions of 
p-Nitrophenyl Phosphate (pNPP) (Sigma-Aldrich, St. Louis, MO, USA) and 1:500 diluted calf intestinal alkaline 
phosphatase (10,000 U/ml). Sample reactions (100 μl) constituted of 10 μl diluted (1:40–1:200) faecal super-
natant, 45 μl assay buffer (0.1 mM  ZnCl2, 1 mM  MgCl2, 10 mM Tris–HCl pH 10.0), and 45 μl 4.56 mM pNPP 
stock. Standards and samples were incubated at + 37 °C for 30 min, where after the reactions were stopped by 
adding 20 μl 3 M NaOH. Absorbances (405/630 nm) were measured with Synergy H1 Microplate Reader. The 
IAP activities were calculated using the formula IAP activity (U/ml) = A/V/T, where A is the amount of pNP 
generated in μmol, V is the sample volume in ml and T is the reaction time in minutes. The final IAP activity 
levels were normalized with the faecal protein concentrations determined by the Lowry method (DC protein 
assay, Bio-Rad, Hercules, CA, USA).
Faecal immunoglobulins. The levels of total IgA, IgG and IgM were determined from the faecal extracts 
by a chemiluminescence immunoassay as described  earlier17, 18. Briefly, supernatants were incubated for 1 h at 
room temperature, and the amount of antibody bound was detected with alkaline phosphatase-labelled goat 
anti-human secondary antibodies for IgA, IgG and IgM (Sigma-Aldrich) using LumiPhos 530 (Lumigen, South-
field, MI, USA) chemiluminescence substrate. The luminescence readings (Victor3 multilabel counter, Perki-
nElmer, Waltham, MA, USA) were expressed as relative light units/100 ms.
Statistics. Data are presented as mean (± SD) for normally distributed and as median [interquartile range] 
for non-normally distributed continuous variables (Tables 1, 2). All non-normally distributed variables were 
log-transformed before analyses. Clinical characteristics were compared across groups using unpaired Students’ 
t  test or ANOVA for continuous variables and the χ2 test for categorical variables. The χ2 test was also used 
to examine the differences between faecal calprotectin-negative and -positive groups (cut-off level < 50  µg/g 
or ≥ 50  µg/g). Differences in the measured clinical variables between faecal calprotectin of below and above 
50 µg/g were tested with Mann–Whitney U test. To test for association of neutrophils and calprotectin, Spear-
man’s rank correlation was used. ANOVA and ANCOVA were applied to assess for differences in the levels of 
calprotectin, SCFA, IAP activity and immunoglobulins between subjects with T1D and controls. These mod-
els were also applied to test for differences among the historical groups of albuminuria (normo-, micro- and 
macroalbuminuria). Unadjusted and adjusted linear regression models were applied to evaluate associations 
between current UACR level analyzed as continuous variable and the faecal biomarkers. All adjusted analyses 
included age, sex, 24-h systolic BP and eGFR. Two-sided p values less than 0.05 were considered as statistically 
significant. The statistical analyses were performed in R Studio version 3.4.1 (R Foundation, Vienna, Austria), 
SAS version 9.4 (Cary, NC, USA) or SPSS version 25.0 (Chicago, IL, USA).
Ethics declaration. The study was conducted in accordance with the Declaration of Helsinki and was 
approved by the Ethics Committee of the Danish Capital Region (protocol H-15018107). All subjects gave writ-
ten informed consent.
Results
Clinical findings. Characteristics of the 209 participants are shown in Table 1. The total cohort included 
87 (42%) females and mean age was 60 (± 11) years. The subjects with T1D had a relatively long diabetes dura-
tion (mean 42 ± 15 years). Subjects with micro- and macroalbuminuria had longer duration than subjects with 
normoalbuminuria. The subjects with normoalbuminuria had higher hsCRP and lower LDL levels than the 
controls. Across the subjects with T1D the 24-h systolic BP,  HbA1C, hsCRP, neutrophils and UACR (as expected) 
were higher with increasing level of albuminuria, and the eGFR was lower. Known history of cardiovascular dis-
ease, retinopathy, and neuropathy were more frequent within increasing level of albuminuria. In the group with 
macroalbuminuria, 48% had known cardiovascular disease, 53% had neuropathy, non-proliferative retinopathy 
was present in 32% and 62% had proliferative retinopathy.
Faecal biomarkers. Faecal calprotectin. Mean faecal calprotectin levels did not differ between T1D sub-
jects and NDC or between the groups of albuminuria (Table 2). However, when subjects were stratified accord-
ing to the calprotectin cut-off level for moderate to severe inflammation according to the  manufacturer15, the 
percentage of subjects showing positive test results for inflammation (> 50 µg/g) were higher among subjects 
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with diabetes and macroalbuminuria than controls: NDC 8%, T1D-normo 18%, T1D-micro 16%, T1D-macro 
26% (NDC vs. T1D-macro; p = 0.02) (Fig. 1). No significant differences were observed in clinical phenotypes 
(BMI, 24-h systolic blood pressure, 24-h diastolic blood pressure, eGFR,  HbA1c, P-LDL cholesterol, ALT, hsCRP, 
and blood neutrophil count), when macroalbuminuric subjects were stratified based on the negative (< 50 µ/g; 
n = 44) and positive (≥ 50 µ/g; n = 15) calprotectin measurements (data not shown). However, within all subjects 
with diabetes, we found a positive association between the faecal calprotectin levels and blood neutrophil count 
(r = 0.195; p = 0.015).
Faecal short‑chain fatty acids. Faecal propionate (C3) and butyrate (C4) levels were significantly lower among 
subjects with T1D (n = 132) than among NDC (n = 40) both in the unadjusted (C3, p = 0.02; C4, p = 0.01) and 
adjusted (C3, p = 0.04; C4, p = 0.03) models. Acetate (C2), valerate (C5) and isobutyrate (iC4) did not differ 
between the T1D and NDC groups. Isovalerate (iC5) levels were significantly higher among subjects with T1D 
Table 1.  Clinical characteristics of the study subjects at the current visit. Data are shown as n (%), 
mean ± standard deviation or as median (interquartile range). ALT alanine transaminase, hsCRP high-
sensitivity C-reactive protein, CD cardiovascular disease. p values were calculated with unpaired Students’ t 
test or analysis of covariance (ANCOVA covariates were age, sex, 24-h systolic blood pressure and eGFR) for 
continuous variables and the χ2 test for categorical variables. a Bristol stool scale from 1 to 7. b Bowel movement 
frequency 1–4; 1 = Twice daily or more, 2 = Once daily, 3 = Every other day and 4 = Less than every other day. 
c No/non-proliferative/proliferative. eGFR estimated glomerular filtration rate, UACR current urinary albumin 
creatinine rate. d Based on results from the three albuminuria measurements at study visit. Albuminuria values 
(e.g. albuminuria category) may be reduced compared to the historic albuminuria measurements due to kidney 
protective treatment.
Controls
All subjects with 
diabetes Normo-albuminuria Micro-albuminuria Macro-albuminuria
p value: controls vs. 
normo-albuminuria
p value: normo- vs. 
micro- vs. macro-
albuminuria
Subjects (N) 50 159 49 50 60
Age (years) 59 ± 13 61 ± 10 60 ± 11 62 ± 9 60 ± 10 0.642 0.652
Female (%) 22 (44) 65 (41) 20 (41) 22 (44) 23 (38) 0.907 0.834
Body mass index 
(kg/m2) 24 ± 3.2 26 ± 4.4 25 ± 4.1 26 ± 4.8 27 ± 4.1 0.258 0.192
24 h systolic blood 
pressure (mmHg) 133 ± 12 137 ± 12 133 ± 10 139 ± 13 139 ± 13 0.920 0.014
24 h diastolic blood 
pressure (mmHg) 80 ± 7 77 ± 6 77 ± 6 76 ± 7 76 ± 6 0.065 0.702
eGFR (ml/min/1.73 
 m2) 89 ± 14 75 ± 25 90 ± 16 81 ± 23 59 ± 23 0.727  < 0.001
UACR (mg/g) 4 (3–5) 14 (5–99) 3 (2–5) 12 (5–33) 152 (53–496) 0.609  < 0.001
Current UACR 







HbA1c (mmol/mol) 36 ± 2.7 61 ± 10.2 60 ± 8.6 60 ± 6.6 64 ± 13.0  < 0.001 0.034
HbA1c (%) 5.4 ± 0.3 7.8 ± 0.9 7.6 ± 0.8 7.7 ± 0.6 8.0 ± 1.2  < 0.001 0.034
P-LDL cholesterol 
(mmol/l) 3.2 ± 0.8 2.2 ± 0.7 2.2 ± 0.6 2.1 ± 0.6 2.1 ± 0.8  < 0.001 0.583
ALT (U/l) 31 ± 7 35 ± 10 33 ± 9 36 ± 11 35 ± 9 0.200 0.283
hsCRP (mg/l) 0.8 (0.5–1.4) 1.6 (0.9–3.2) 1.1 (0.7–2.4) 1.6 (1.1–3.2) 2.1 (1.1–3.4) 0.048 0.005
Neutrophil count 3.2 (3–4) 3.8 (3–5) 3.3 (3–4) 4.0 (3–5) 4.3 (3–6) 0.039 0.003
Smoking (%) 0.455 0.212
Current 4 (8) 23 (15) 7 (15) 8 (16) 8 (14)
Previous 23 (46) 68 (45) 17 (37) 19 (39) 32 (57)
Never 23 (46) 60 (40) 22 (48) 22 (45) 16 (29)
Alcohol (beverages/
week) 7 (3–14) 7 (3–14) 7 (4–15) 7 (5–14) 7 (2–12) 0.596 0.314
Bristol stool  scalea 4 (3–4) 3 (3–4) 3 (3–4) 3 (2.25–3) 3 (2–3.5) 0.487 0.065
Bowel movement 
 frequencyb 2 (1–2) 2 (2–2) 2 (2–2) 2 (2–2) 2 (1–2) 0.459 0.499
Diabetes characteristics
Diabetes duration 
(years) – 42 ± 15 34 ± 15 46 ± 14 44 ± 13 –  < 0.001
History of CD (%) – 47 (23) 8 (16) 10 (20) 29 (48) –  < 0.001
Retinopathyc (%) – 22/36/41 46/45/6 18/32/50 5/32/62 –  < 0.001
Neuropathy (%) – 51 (32) 6 (12) 13 (26) 32 (53) –  < 0.001
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compared to NDC in the unadjusted analysis (p = 0.03), but this association disappeared after adjustment. iC4 
and iC5 correlated positively with each other (p < 0.01). The SCFA/BCFA-ratio was significantly lower among 
Table 2.  Fecal biomarkers in (A) subjects with T1D and controls and (B) per historical albuminuria categories 
(normo-, micro- and macroalbuminuria). Data is shown as median (interquartile range).  Log10-transformed 
values were used for all biomarkers. SCFA the sum of short chain fatty acids C2, C3, C4 and C5, BCFA the 
sum of branched short chain fatty acids iC4 and iC5, IAP intestinal alkaline phosphatase, Ig immunoglobulin, 
FM fecal mass. Significant differences between groups are shown in bold. p values were calculated by unpaired 
Students’ t test for group-wise differences (Table b), ANOVA and ANCOVA (ANCOVA covariates were age, 
sex, 24-h systolic blood pressure and eGFR).
(A) Biomarker
Controls All T1D subjects p value: 
ANOVA
p value: 
ANCOVAValue N Value N
Calprotectin 
(µg/g) 6.0 (2.0–37) 50 11 (0–23) 158 NS NS
IAP (U/l) 71 (46–172) 50 65 (34–183) 159 NS NS
Fecal protein 
(mg/ml) 2.2 (1.7–3.9) 50 2.4 (1.8–3.0) 159 NS NS
Acetate (C2) 




11 (9.0–15) 40 9 (7.0–12) 132 0.02 0.04
Butyrate (C4) 
(µmol/g FM) 11 (8.1–16) 40 7.8 (4.7–12) 132 0.01 0.03
Valerate (C5) 








2.2 (1.7–2.9) 40 2.6 (1.9–3.5) 132 0.03 NS
SCFA/BCFA 
(µmol/g FM) 16 (10–17) 40 13 (12–26) 132 0.001 NS
IgA (µg/ml) 2.6 (0.8–7.3) 50 2.6 (0.9–7.8) 157 NS NS
IgG (ng/ml) 33 (12–74) 49 32 (15–79) 149 NS NS


















ANCOVAValue N Value N Value N
Calprotectin 
(µg/g) 14 (3.7–39) 49 11 (0–34) 50 8.4 (2.0–60) 59 NS NS NS NS NS
IAP (U/l) 64 (39–238) 49 63 (32–153) 50 74 (37–231) 60 NS NS NS NS NS
Fecal protein 
(mg/ml) 2.5 (1.8–3.3) 49 2.6 (2.0–3.1) 50 2.2 (1.7–2.9) 60 NS NS NS NS NS
Acetate (C2) 




9.6 (6.0–12.6) 40 9.7 (6.8–12.4) 42 9.1 (6.8–11.8) 50 NS NS NS NS NS
Butyrate (C4) 
(µmol/g FM) 7.5 (4.5–14.5) 40 9.0 (5.6–12.0) 42 7.0 (4.7–11.0) 50 NS NS NS NS NS
Valerate (C5) 








2.3 (1.7–2.7) 40 3.0 (2.2–3.6) 42 2.7 (1.9–3.8) 50 0.03 NS 0.05 NS NS
SCFA/BCFA 
(µmol/g FM) 13.3 (11–19) 40 12.0 (9.9–17.4) 42 12.2 (9.6–16) 50 NS NS NS NS NS
IgA (µg/ml) 2.2 (0.8–8.9) 49 3.6 (0.9–7.3) 49 2.8 (0.9–8.4) 59 NS NS NS NS NS
IgG (ng/ml) 38 (18–61) 44 26 (8.0–66) 49 33 (13–108) 56 NS NS NS NS NS
IgM (µg/ml) 0.2 (0.1–0.7) 47 0.3 (0.1–0.8) 46 0.3 (0.1–1.4) 58 NS NS NS NS NS
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subjects with T1D than among NDC in the unadjusted model (p = 0.001), however, not after adjustment (Fig. 2, 
Table 2A).
In the subjects with T1D, levels of C2, C3, C4, and C5 did not differ with respect to albuminuria, neither 
when analyzed within historical albuminuria groups (Table 2B) or as current UACR (data not shown). BCFA 
were higher with increasing albuminuria in unadjusted models: iC4 (normo vs. micro; p = 0.02), iC5 (normo vs. 
micro; p = 0.03), and iC5 (normo vs. macro; p = 0.05), but not after adjustment (Table 2B). Moreover, the BCFA 
correlated positively with current UACR in the unadjusted (iC4:  R2 = 0.03, p = 0.02; iC5:  R2 = 0.05, p = 0.004) as 
well as the adjusted (iC4:  R2 = 0.35, p = 0.03; iC5:  R2 = 0.36, p = 0.005) models (Fig. 3).
Faecal IAP activity and immunoglobulins. Faecal IAP activity and immunoglobulin (total IgA, IgG and IgM) 
levels did not differ between the study groups (Table 2).
Discussion
The aim of the present study was to investigate whether faecal markers of gut metabolism are associated with 
albuminuria in Danish T1D subjects with and without diabetic nephropathy. We observed that mean faecal cal-
protectin, IAP and immunoglobulin levels did not differ between the T1D albuminuria groups. However, when 
the presence of moderate to severe inflammation was evaluated individuals with T1D and macroalbuminuria 
showed positive calprotectin levels (> 50 µg/g) three times more often compared to non-diabetic controls. Fur-
thermore, subjects with T1D as a whole group had lower levels of the faecal propionate and butyrate compared 
to the healthy subjects. Taken together, our main results indicate that the T1D subjects, particularly those with 
macroalbuminuria, showed unfavorable changes in gut homeostasis.
Faecal calprotectin has become a valuable diagnostic tool for IBD due to its correlation with the activity and 
severity of the  disease19, 20. More attention should be paid to the systematic screenings of gut related illnesses, 
especially in patient groups with chronic systemic diseases, as the incidence of IBD is increasing  globally21. To 
date, there are very few studies, which have performed systematic screenings of IBD among subjects with  T2D22. 
There is growing evidence showing that faecal calprotectin could be a useful biomarker in the assessment of 
intestinal health conditions in various metabolic disorders e.g. T1D, T2D, and  obesity17, 23, 24. Gastrointestinal 
symptoms (e.g. early satiety, postprandial fullness, nausea, abdominal pain, vomiting, bloating, diarrhea and/
or constipation) are common in subjects with  diabetes25. In our study, higher faecal calprotectin was associated 
with a higher blood neutrophil count among the subjects with type 1 diabetes. One could speculate that this 
represents an association between intestinal inflammation (elevated levels of faecal calprotectin) and low-grade 
systemic inflammation (a higher number of circulating neutrophils). Increased systemic inflammation has been 
associated with more rapid progression of chronic kidney  disease26, 27. In relation to the development of dia-
betic complications, the role of gut-related diseases remains obscure. We observed that a higher proportion of 
subjects with T1D and macroalbuminuria had elevated levels of faecal calprotectin compared to non-diabetic 
controls, which could be interpreted as an early sign of gastrointestinal inflammation. What could be possible 
explanations for the elevated faecal calprotectin values in subjects with macroalbuminuria? T1D subjects with 
micro- and macrovascular complications use more often antibiotics and have higher systemic endotoxin levels 
compared to those without diabetic  complications28–31. Changes in lifestyle related factors (e.g. diet, physical 
activity, medication etc.) may increase the risk of gut dysbiosis, which could eventually lead to expansion of 
pathogenic bacteria. It is also evident that decreased intestinal barrier function in combination with leakage 
of gut derived microbial toxins could accelerate and aggravate cardiovascular disease and kidney impairment 
including elevated albuminuria. On the other hand, kidney impairment with following accumulation of toxic 
metabolites (e.g. uremic compounds) in chronic kidney disease, may also have deleterious effects on the  gut32. 
Thus, pathophysiological mechanisms related to the gut-kidney axis could be bidirectional. The fact that we did 
not observe any significant differences among individuals with T1D and different levels of albuminuria could 
have different reasons including: (1) the number of study subjects were too low; and (2) the albuminuria groups 
Figure 1.  Faecal calprotectin measurements. The proportion of calprotectin positive individuals [expressing 
either moderate (> 50 μg/g) or high (> 200 μg/g) calprotectin levels] was higher in the macroalbuminuria group 
compared to controls. Control healthy nondiabetic controls, Normo T1D subjects with normal albuminuria, 
Micro T1D subjects with microalbuminuria, Macro T1D subjects with macroalbuminuria. #p < 0.05.
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Figure 2.  Faecal short chain fatty acids (SCFA). Acetate (C2), valerate (C5), isobutyrate (iC4) and isovalerate 
(iC5) levels did not differ between subjects with T1D and controls. Propionate (C3) and butyrate (C4) levels and 
the SCFA/BCFA -ratio were significantly lower among the subjects with diabetes compared to controls. SCFA 
(sum of C2, C3, C4 and C5), and branched SCFA (BCFA) (sum of iC4 and iC5). Only relevant significances 
between the controls (n = 40) and disease groups (Normo, n = 40; Micro, n = 42; Macro, n = 50; T1D, n = 132) are 
shown. #p < 0.05; *p < 0.01; **p < 0.001.
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were relatively well-treated as the measured median (IQR) albuminuria levels were 12 (5–33) and 152 (53–496) 
for the micro- and macroalbuminuria groups, respectively. We observed that the proportion of macroalbu-
minuric subjects with positive test result for calprotectin (> 50 µg/g) was higher compared to NDC. However, 
faecal calprotectin was not, as we would have expected, associated with current albuminuria levels. The lack of 
association between continuous calprotectin and albuminuria measures are most likely explained by the non-
linear behaviour of these parameters and the small sample size.
In the present study, T1D subjects with kidney disease displayed lower faecal propionate and butyrate levels 
compared to NDC, which could be explained by observed changes in gut microbiota  composition10. These results 
are also in line with our earlier findings—faecal propionate and butyrate levels were lower in Finnish T1D subjects 
compared to non-diabetic healthy  controls17. The abundant SCFA acetate, propionate and butyrate, contribute to 
the regulation of glucose and lipid  homeostasis33–35 by ligating to free fatty acid receptors (e.g. FFAR2) located 
on hematopoietic, stromal and intestinal epithelial cells. Their binding regulates the inflammasome, the main 
component of the functional innate immune  system36. Propionate levels have previously been linked to satiety 
and the risk of obesity and insulin  resistance37. High levels of propionate reduce food intake by stimulating the 
expression of gut hormones peptide YY (PYY) and glucagon-like peptide 1 (GLP-1)38. Life-style related factors, 
e.g. high carbohydrate intake, has been associated with decreased levels of faecal propionate and butyrate in 
subjects with type 2  diabetes39. Butyrate inhibits the activity of histone-deacetylase complex, responsible for 
transcription and chromatin remodeling, through which it activates regulatory T cells in immunity. It controls 
pathogens also directly in the intestine by reinforcing tight junctions, hereby increasing the barrier to patho-
gens. Previous studies have shown that butyrate-producing bacteria in the gut are less abundant in subjects 
with  T1D40–42 as well as in subjects with chronic kidney  disease43, 44. Future studies will be needed in order to 
Figure 3.  Branched short chain fatty acids (isobutyrate, iC4 and isovalerate, iC5) per urinary albumin to 
creatinine ratio (UACR). Both iC4 (A) and iC5 (B) correlated with UACR (iC4:  R2 = 0.03, p = 0.02; iC5:  R2 = 0.05, 
p = 0.004) in the unadjusted as well as in the adjusted model (iC4:  R2 = 0.35, p = 0.03; iC5:  R2 = 0.36, p = 0.005). 
The analyses were adjusted with age, sex, 24-h systolic blood pressure and estimated glomerular filtration rate. 
FM fecal mass. 95% CI around the regression line is shown in grey.
9
Vol.:(0123456789)
Scientific Reports |        (2021) 11:15208  | https://doi.org/10.1038/s41598-021-94747-8
www.nature.com/scientificreports/
uncover whether changes in dietary factors, medication, physical activity etc. will explain the observed changes 
in intestinal SCFA-levels in individuals with diabetic kidney disease.
Faecal concentrations of the BCFA, isobutyrate (iC4) and isovalerate (iC5), correlated positively with albumi-
nuria in our study. BCFA originate from bacterial degradation of proteins in the colon, while the SCFA (C2–C5) 
originate from carbohydrate  breakdown45. The fact that iC4 and iC5 correlated with each other could indicate 
that their metabolic functions are different from those of the linear SCFA (C2–C5)46. It has been suggested that 
a decrease in the SCFA/BCFA-ratio might reflect unfavorable conditions, where the local SCFA production is 
reduced at the expense of increased amino acid  fermentation47. We observed that the SCFA/BCFA-ratio was 
significantly lower among the subjects with T1D compared to the healthy controls. It is of note that clinical tri-
als with pre- and probiotics have shown potential therapeutic effects in the management of various metabolic 
 diseases48, 49, but further evidence regarding their beneficial effects in general and in T1D is needed. In subjects 
with ulcerative colitis, oral supplementation of inulin-type beta-fructans for 9 weeks improved colon health 
and increased colonic butyrate (C4), whereas the isobutyrate (iC4) and isovalerate (iC5) levels were markedly 
 decreased50. Moreover, increased faecal levels of iC4 and iC5 have been linked to unfavorable changes in the 
composition of serum lipids and gut microbiota in subjects with  hypercholesterolemia51.
We examined the fecal biomarkers in relations to diabetic nephropathy both as historic albuminuria levels 
(divided in groups) as well as measured current level of albuminuria. The results for associations with the fecal 
biomarkers were consistent for both measurements, however for the BCFA results, the association with current 
albuminuria remained significant after adjustment. This may be explained by loss of power in the group division, 
however an explanation could also be the fact that the BCFA are reflective of the situation at the time, when the 
current albuminuria status was recorded. The historic albuminuria level reflects worst ever status. However, the 
historic level is modified by treatment with renin–angiotensin–aldosterone system (RAAS) inhibitors which is 
reflected in the current albuminuria status. We do not know whether a reduction in the albuminuria level with 
RAAS inhibitors improves renal histology or just perform hemodynamic modifications leading to albuminuria 
reductions and whether such modifications could alter other features such as BCFA.
In contrast to our previous study in Finnish subjects with  T1D17, we did not observe differences in the IAP 
activity or immunoglobulin levels between Danish T1D and NDC, or within the level of albuminuria. A reason 
for this discrepancy may be due to differences in the two cohorts studied. The Finnish macroalbuminuric sub-
jects had higher median albuminuria level compared to the Danish cohort (978 [231–2812] vs. 152 [53–496]) 
suggesting more advanced disease.
This study has also limitations. The design is cross-sectional, which does not allow to evaluate direct causality 
between gut related biomarkers and progression of diabetic nephropathy. The primary aim of the study was to 
investigate faecal biomarkers, however, future data on gut microbiome, metaproteomics, and faecal metabolomics 
have not been possible to include in the current analysis. Such data might have helped to create a more compre-
hensive picture of the gut-related phenotypes. In addition, the lacking information of nutrition or dietary habits, 
could have had an influence on the faecal biomarkers. Therapies targeting diabetes (inflammation, dyslipidemia, 
poor glucose control etc.) and kidney disease (albuminuria, blood pressure etc.) could also have beneficial effects 
on the gastrointestinal health, which may lead to underestimation of the effects.
Conclusions and future directions
In the present study, we found putative associations between gut biomarkers, T1D and the presence of kidney 
complications. Subjects with T1D showed unfavorable intestinal SCFA levels compared to healthy controls. In 
the T1D group, BCFA were positively associated with albuminuria. Moreover, subjects with T1D and macroal-
buminuria had more frequently elevated levels of faecal calprotectin although the mean levels were not different 
between the groups. These observations may reflect that gastrointestinal diseases could play a significant role 
also in diabetic nephropathy at an early stage. Our observations together with previous findings suggest that 
gastrointestinal problems related to low-grade inflammation and dysbiosis might be more common in T1D than 
previously anticipated. To disentangle the putative interconnections between the gut and the kidney related dis-
orders as well as incidence and severity of gastrointestinal related symptoms in subjects with T1D, longitudinal 
follow-up and intervention studies are needed.
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